With GLP-1 receptor agonists dominating the obesity treatment landscape, the pharmaceutical industry is now turning its attention to next-generation therapies such as amylin analogues, multi-target agonists, and gene and nucleic acid therapies. However, the complexity of these novel mechanisms poses a significant challenge to traditional preclinical platforms, which often fail to provide the predictive accuracy needed to guide development. Recognizing this translational gap, Protheragen Obesity has announced a comprehensive suite of next-generation precision obesity models designed to improve R&D efficiency and clinical success rates.
Traditional diet-induced obesity (DIO) models have long been the standard, but they carry inherent limitations. Classical evaluation systems tend to focus heavily on macroscopic endpoints like changes in body weight and food intake, while overlooking critical pharmacodynamic dimensions such as body composition (muscle-to-fat ratio), energy metabolic homeostasis, dynamic changes in insulin sensitivity, and target organ histopathology (e.g., hepatic steatosis, adipose tissue macrophage infiltration). This narrow focus likely contributes to the high attrition rate of compounds that perform well in preclinical studies but fail in clinical trials due to efficacy or safety concerns.
The maturation of CRISPR/Cas9 gene editing technology is reshaping model development. Gene editing-based obesity models now enable precise recapitulation of human obesity-associated genetic mutations in pathways such as LEP, LEPR, and MC4R. These models provide previously unavailable validation platforms: humanized models support antibody target validation, while conventional knockout/knock-in models enable mechanistic studies of target biology. The model selection paradigm has thus evolved from simple availability to precision matching based on mechanism of action.
To address the diverse requirements across different development stages and target types, Protheragen Obesity has established a tiered, customizable technical system. This includes in vitro cell models (e.g., 3T3-L1 preadipocyte differentiation system, primary adipocyte and hepatocyte co-culture platforms) for high-throughput screening and signaling pathway studies; gene-edited models (single/multi-gene mutations, transgenic, and humanized replacement) for antibody and gene therapy vector validation; diet-induced models (high-fat, high-sugar, and high-fat combined with low-dose STZ for obesity with type 2 diabetes comorbidities) for standardized small-molecule efficacy evaluation; and chemically induced and surgically induced models (hypothalamic injury and ovariectomy) for specific mechanistic questions. Each model is equipped with a comprehensive metabolic phenotyping system covering DEXA/MRI body composition monitoring, indirect calorimetry, glucose and insulin tolerance testing (GTT and ITT), and histopathological examination, ensuring data traceability and cross-experimental comparability.
Protheragen Obesity operates under a GLP-compliant quality management system. For DIO studies—which typically run 8 to 16 weeks—the model induction success rate exceeds 90%. For gene-edited models, the company provides comprehensive genotyping reports, copy number and integration site analysis, and germline transmission validation data. All study reports meet FDA and NMPA requirements for IND-enabling pharmacology submissions.
The company offers flexible collaboration models: full-service outsourcing (from model construction to data analysis), modular services (clients purchase specific components as needed), and co-development partnerships (joint investment in novel model development). Every engagement begins with a consultation phase where the technical team works directly with client researchers to understand the molecular modality, mechanism of action, and regulatory pathway, then customizes the optimal model strategy. With extensive experience in metabolic disease research, Protheragen Obesity has supported dozens of biopharmaceutical companies in completing obesity drug development programs from target validation to IND submission.
